Having recently inked a world-first deal with NHS England for its investigational new cholesterol treatment inclisiran, acquired through the $9.7bn purchase of The Medicines Co., Novartis AG's senior management has been musing on how similar population-based agreements could transform the way big pharma and healthcare systems do business.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?